This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Intravenous immunoglobulin (IVIG) treatment for dermatologic conditions shows effectiveness but poses risks of kidney decline and thromboembolism, necessitating careful monitoring.
Pharmaceutical websites serve a dual purpose: delivering trusted medical content and capturing the attention of health care professionals (HCPs), patients, and researchers. However, traditional search functions often fall short. Visitors can’t find what they need, content goes unseen, and bounce rates increase. This is where AI-driven search can transform the user experience and drive real results for pharma marketers.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when treated with bulevirtide maintained suppression for nearly two years.
Oscar Health's stock increased by 30% after its first quarter earnings, but company executives weighed in on the potential adverse consequences of cost-sharing reductions, ACA enhanced subsidy expirations and a shortened enrollment window.
The UK and India have agreed a major trade deal, however it does not provide sufficient support the UK pharmaceutical industry, according to the Association of the British Pharmaceutical Industry (ABPI). While the UK government considers the agreement to be the UKs largest and most economically significant bilateral trade deal since its EU exit in 2020, the industry body argued that it does not address key areas such as intellectual property protections for innovators within the Indian market.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
The UK and India have agreed a major trade deal, however it does not provide sufficient support the UK pharmaceutical industry, according to the Association of the British Pharmaceutical Industry (ABPI). While the UK government considers the agreement to be the UKs largest and most economically significant bilateral trade deal since its EU exit in 2020, the industry body argued that it does not address key areas such as intellectual property protections for innovators within the Indian market.
WASHINGTON — The White House is withdrawing the nomination of former Fox News medical contributor Janette Nesheiwat for U.S. surgeon general, marking at least the second health-related pick from President Donald Trump to be pulled from Senate consideration. The withdrawal was confirmed by two people familiar with the matter.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.
Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs potential into new therapeutic areas.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have a chance to lead aligning innovation with access drivers and gaining a competitive edge in a changing global landscape.
In an era where attention spans are shorter and healthcare stakeholders are increasingly digital-first, executing pharma marketing strategies that truly deliver ROI is both a challenge and a necessity. How do pharmaceutical brands cut through the clutter, earn HCP trust, and engage patients effectively? The answer lies in combining proven fundamentals with innovative tools and omnichannel integration.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs potential into new therapeutic areas.
Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.
The aura6000 system showed a 65% responder rate at 12 months in patients with obstructive sleep apnea, defined as achieving at least a 50% reduction in apnea-hypopnea index.
AI transforms pharmacy practice by streamlining workflows and enhancing patient care, while pharmacists adapt to new roles and challenges in health care.
When treating herpes simplex virus (HSV) or varicella-zoster virus (VZV), two antiviral agents commonly used are acyclovir and valacyclovir. While both medications are effective, understanding their pharmacokinetic profiles, dosage forms, and clinical uses can help healthcare providers make the best choice for each patient. In this blog post, I will highlight the most important differences […] The post Acyclovir Versus Valacyclovir – What’s the Difference?
A federal judge has sided with the U.S. Food and Drug Administration over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes treatment — from a shortages list kept by the agency. The move means that patients will no longer have access to cheaper versions from compounding pharmacies.
In January, San Francisco’s Union Square was bustling with hordes of drug developers and investors, pounding the pavement on their way from meeting to meeting. But Rohan Ganesh, an investor at the VC firm Obvious Ventures, wasn’t among them. He only agreed to hear one company’s pitch during this year’s J.P. Morgan Healthcare Conference.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content